CD14⁺HLA‐DR low/⁻ monocytes as indicator of disease aggressiveness in B‐cell non‐Hodgkin lymphoma

Abstract

Increased CD14(+) monocytes with loss of HLA expression were seen in patients with higher stage disease, more aggressive pathology, and in relapse or refractoriness to treatment. Identifying therapeutic strategies to overcome the suppressive properties of these monocytes could be of value.

Immune independent crosstalk between lymphoma and myeloid suppressor CD14+HLA-DRlow/negmonocytes mediates chemotherapy resistance

“…5,[8][9][10]12,14 We hypothesized that CD14 C HLA-DR low/neg monocytes adopt this phenotype through tumor-mediated factors. We found that lymphoma tumors are frequently heavily infiltrated with CD14 C cells (Fig.…”

“…5,13 In addition, decreased presence of these cells is associated with improved clinical response to treatments. 12,14 In this study, we examined lymphoma and monocyte crosstalk that promote lymphoma survival. Using mouse models to mimic our previous findings is difficult.…”

Serum protein profiling in diffuse large B‐cell lymphoma

“…CD14 is a myeloid differentiation marker expressed primarily on monocytes/macrophages. Recently, it was shown that NHL patients with a more aggressive disease phenotype exhibited high expression of CD14 and low expression of HLA‐DR (CD14 + HLA‐DR − /low) that suppresses normal immune function and the proliferation of normal T‐cells . Moreover, lymphoma cells treated with CD14 + HLA‐DR − /low monocytes exhibited chemotherapeutic resistance to doxorubicin.…”

Metabolic Regulation of Myeloid-Derived Suppressor Cell Function in Cancer

“…Multiple myeloma PMN-MDSCs are induced by multiple myeloma-related mesenchymal stem cells to have high expression of ARG1 and exert immunosuppressive function in tumor [103] Multiple myeloma PMN-MDSCs limit the anti-tumor response of T cells by increase the expression of ARG1 and other suppressive molecules, which is correlated with the expression of IL-18 [104] Head and neck cancer and urological cancers Overexpression of fatty acid transport protein 2 (FATP2) in PMN-MDSCs is conductive to tumor growth by the synthesis of PGE2 [29] Lymphomas are malignant tumors derived from the lymphatic hematopoietic system and are divided into Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) [106]. Several studies have uncovered that in NHL, including B cell NHL, diffuse large B cell lymphoma and NK/T cell NHL, increased expression of ARG1, IDO and iNOS in MDSCs is relevant to the enhancement of tumor growth and suppression of T cells [107][108][109][110]. However, little is known about whether the metabolic regulation of MDSCs participates in HL [111].…”